JP2019530656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019530656A5 JP2019530656A5 JP2019511707A JP2019511707A JP2019530656A5 JP 2019530656 A5 JP2019530656 A5 JP 2019530656A5 JP 2019511707 A JP2019511707 A JP 2019511707A JP 2019511707 A JP2019511707 A JP 2019511707A JP 2019530656 A5 JP2019530656 A5 JP 2019530656A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- och
- optionally substituted
- absent
- terminal nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 55
- 239000002773 nucleotide Substances 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 28
- 239000002777 nucleoside Substances 0.000 claims 21
- -1 nucleoside phosphoramidite Chemical class 0.000 claims 21
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 229910052760 oxygen Inorganic materials 0.000 claims 10
- 108010024636 Glutathione Proteins 0.000 claims 9
- 229960003180 glutathione Drugs 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000006239 protecting group Chemical group 0.000 claims 8
- 108091081021 Sense strand Proteins 0.000 claims 7
- 230000000692 anti-sense effect Effects 0.000 claims 7
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 claims 6
- 108091030071 RNAI Proteins 0.000 claims 6
- 230000009368 gene silencing by RNA Effects 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 230000000295 complement effect Effects 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 150000008300 phosphoramidites Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229940124447 delivery agent Drugs 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 229910052711 selenium Inorganic materials 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 125000003843 furanosyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 2
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 239000000074 antisense oligonucleotide Substances 0.000 claims 1
- 238000012230 antisense oligonucleotides Methods 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 0 BC(C(*)C1O*)OC1OCP(*)(*)=O Chemical compound BC(C(*)C1O*)OC1OCP(*)(*)=O 0.000 description 8
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021180199A JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383207P | 2016-09-02 | 2016-09-02 | |
| US62/383,207 | 2016-09-02 | ||
| US201662393401P | 2016-09-12 | 2016-09-12 | |
| US62/393,401 | 2016-09-12 | ||
| PCT/US2017/049909 WO2018045317A1 (en) | 2016-09-02 | 2017-09-01 | 4'-phosphate analogs and oligonucleotides comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180199A Division JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019530656A JP2019530656A (ja) | 2019-10-24 |
| JP2019530656A5 true JP2019530656A5 (enExample) | 2020-04-09 |
| JP6978099B2 JP6978099B2 (ja) | 2021-12-08 |
Family
ID=61301649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019511707A Active JP6978099B2 (ja) | 2016-09-02 | 2017-09-01 | ４’−リン酸アナログ及びそれを含むオリゴヌクレオチド |
| JP2021180199A Withdrawn JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021180199A Withdrawn JP2022017481A (ja) | 2016-09-02 | 2021-11-04 | ４’－リン酸アナログ及びそれを含むオリゴヌクレオチド |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11414659B2 (enExample) |
| EP (2) | EP3506909B1 (enExample) |
| JP (2) | JP6978099B2 (enExample) |
| KR (2) | KR102350647B1 (enExample) |
| CN (1) | CN110072530B (enExample) |
| AU (1) | AU2017321892A1 (enExample) |
| CA (1) | CA3033756A1 (enExample) |
| DK (1) | DK3506909T3 (enExample) |
| ES (1) | ES2924806T3 (enExample) |
| HU (1) | HUE059718T2 (enExample) |
| IL (2) | IL264887B (enExample) |
| MX (1) | MX2019002339A (enExample) |
| PL (1) | PL3506909T3 (enExample) |
| PT (1) | PT3506909T (enExample) |
| WO (1) | WO2018045317A1 (enExample) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3527670T (pt) * | 2013-03-15 | 2024-01-18 | Beth Israel Deaconess Medical Ct Inc | Biogénese de mirna em exossomas para diagnóstico e terapia |
| US11110180B2 (en) | 2017-10-04 | 2021-09-07 | Avidity Biosciences Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CN111971051A (zh) | 2018-04-13 | 2020-11-20 | 迪克纳制药公司 | 用增加tm的核苷酸修饰的双链核酸抑制剂分子 |
| CN113454221A (zh) * | 2018-12-12 | 2021-09-28 | 迪克纳制药公司 | 含有三元环的双链核酸抑制剂分子 |
| AU2019417585A1 (en) * | 2018-12-28 | 2021-07-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting HMGB1 expression |
| SG11202110174PA (en) | 2019-03-29 | 2021-10-28 | Dicerna Pharmaceuticals Inc | Compositions and methods for the treatment of kras associated diseases or disorders |
| WO2020206350A1 (en) | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| AU2020268798A1 (en) * | 2019-05-03 | 2021-11-04 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| US20220211743A1 (en) | 2019-05-17 | 2022-07-07 | Alnylam Pharmaceuticals, Inc. | Oral delivery of oligonucleotides |
| CA3142283A1 (en) * | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| CA3163857A1 (en) * | 2020-01-15 | 2021-07-22 | Weimin Wang | 4'-o-methylene phosphonate nucleic acids and analogues thereof |
| GEP20257742B (en) | 2020-03-06 | 2025-03-10 | Aligos Therapeutics Inc | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| US20230287425A1 (en) | 2020-03-18 | 2023-09-14 | Dicerna Pharmacuticals Inc. | Compositions and methods for inhibiting angptl3 expression |
| CA3179931A1 (en) | 2020-04-10 | 2021-10-14 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules and uses thereof for coronavirus diseases |
| CA3187220A1 (en) | 2020-08-04 | 2022-02-10 | Dicerna Pharmaceuticals, Inc. | Systemic delivery of oligonucleotides |
| AU2021321430A1 (en) | 2020-08-04 | 2023-03-02 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting PLP1 expression |
| TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
| TW202535432A (zh) | 2020-08-05 | 2025-09-16 | 美商戴瑟納製藥股份有限公司 | 抑制lpa表現之組合物及方法 |
| AU2021322891A1 (en) | 2020-08-05 | 2023-03-09 | Dicerna Pharmaceuticals, Inc. | Oligonucleotide treatment of hepatitis B patients |
| MX2023004109A (es) | 2020-10-08 | 2023-06-28 | Dicerna Pharmaceuticals Inc | Administracion selectiva de oligonucleótidos a células gliales. |
| CA3214439A1 (en) | 2021-04-12 | 2022-10-20 | Boehringer Ingelheim International Gmbh | Compositions and methods for inhibiting ketohexokinase (khk) |
| WO2022221430A1 (en) | 2021-04-14 | 2022-10-20 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating pnpla3 expression |
| MX2023012086A (es) | 2021-04-19 | 2023-10-25 | Novo Nordisk As | Composiciones y metodos para inhibir la expresion del miembro 3 del grupo h de la subfamilia 1 de receptores nucleares (nr1h3). |
| MX2023013504A (es) | 2021-05-28 | 2024-02-23 | Novo Nordisk As | Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1). |
| CA3224145A1 (en) | 2021-06-24 | 2022-12-29 | Melissa Ann Bellinger | Novel rna therapeutics and uses thereof |
| US12465647B2 (en) | 2021-08-05 | 2025-11-11 | Sanegene Bio Usa Inc. | 1′-alkyl modified ribose derivatives and methods of use |
| TW202308660A (zh) | 2021-08-25 | 2023-03-01 | 美商戴瑟納製藥股份有限公司 | 用於抑制α－１抗胰蛋白酶表現之組合物及方法 |
| US20250011789A1 (en) | 2021-09-08 | 2025-01-09 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| CN118201942A (zh) | 2021-09-08 | 2024-06-14 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸(siNA)分子和其用途 |
| AU2022352676A1 (en) | 2021-09-22 | 2024-03-14 | Sanegene Bio Usa Inc. | 2'-alkyl or 3'- alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides |
| JP2024542929A (ja) | 2021-10-05 | 2024-11-19 | セーンジーン バイオ ユーエスエー インコーポレイティド | ポリヒドロキシル化されたシクロペンタン誘導体及び使用方法 |
| EP4441218A2 (en) | 2021-12-01 | 2024-10-09 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating apoc3 expression |
| EP4201947A1 (en) | 2021-12-22 | 2023-06-28 | F. Hoffmann-La Roche AG | Process for the backbone deprotection of oligonucleotides containing a terminal alkyl phosphonate group |
| US20250074933A1 (en) * | 2022-01-05 | 2025-03-06 | Rona Bioscience, Limited | Double-stranded rna having nucleotide analog |
| JP2025508785A (ja) | 2022-02-22 | 2025-04-10 | セーンジーン バイオ ユーエスエー インコーポレイティド | ５’修飾炭素環式リボヌクレオチド誘導体及び使用方法 |
| CN118891266A (zh) | 2022-03-18 | 2024-11-01 | 迪克纳制药公司 | 使用Mn（II）或Mn（III）试剂用于合成4’-乙酰氧基-核苷的脱羧乙酰氧基化及其用于合成相应的4’-(二甲氧基磷酰基)甲氧基-核苷酸的用途 |
| CA3245064A1 (en) | 2022-04-15 | 2023-10-19 | Dicerna Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS OF MODULATING THE ACTIVITY OF STRUCTURAL AND CYTOSKELETON-ASSOCIATED PROTEINS |
| WO2023208023A1 (zh) * | 2022-04-26 | 2023-11-02 | 上海拓界生物医药科技有限公司 | 氘代化学修饰和包含其的寡核苷酸 |
| WO2023220561A1 (en) | 2022-05-09 | 2023-11-16 | Sanegene Bio Usa Inc. | Double stranded rna targeting 17-beta hydroxysteroiddehydrogenase 13 (hsd17b13) and methods of use thereof |
| EP4522747A1 (en) | 2022-05-12 | 2025-03-19 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting mapt expression |
| US20230416743A1 (en) | 2022-05-13 | 2023-12-28 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting snca expression |
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| WO2024015796A1 (en) | 2022-07-11 | 2024-01-18 | Sanegene Bio Usa Inc. | Optimized 2'- modified ribose derivatives and methods of use |
| AU2023320578A1 (en) | 2022-08-05 | 2025-02-13 | Sanegene Bio Usa Inc. | Double stranded rna targeting angiotensinogen (agt) and methods of use thereof |
| WO2024040041A1 (en) | 2022-08-15 | 2024-02-22 | Dicerna Pharmaceuticals, Inc. | Regulation of activity of rnai molecules |
| TW202430191A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療伴有晚期纖維化及/或硬化之nash的方法 |
| TW202430192A (zh) | 2022-10-11 | 2024-08-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療nash之劑量方案 |
| IL320218A (en) | 2022-10-14 | 2025-06-01 | Sanegene Bio Usa Inc | Small interfering RNA targeting C3 and its uses |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| KR20250110896A (ko) * | 2022-11-23 | 2025-07-21 | 일라이 릴리 앤드 캄파니 | 4'-포스페이트 유사체 뉴클레오티드 포스포르아미다이트의 합성 방법 |
| EP4635967A1 (en) * | 2022-12-13 | 2025-10-22 | Tuojie Biotech (Shanghai) Co., Ltd. | Oligonucleotide comprising lipophilic monomer and use thereof in non-liver delivery |
| CN120569477A (zh) | 2022-12-19 | 2025-08-29 | 美国圣因生物股份有限公司 | 靶向cfb的小干扰rna及其用途 |
| TW202438088A (zh) | 2022-12-21 | 2024-10-01 | 美商美國禮來大藥廠 | 新穎FAS RNAi治療劑及其用途 |
| EP4638746A1 (en) | 2022-12-23 | 2025-10-29 | Eli Lilly and Company | Novel rna therapeutics and uses thereof |
| US20250382615A1 (en) | 2022-12-23 | 2025-12-18 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| CN118271378A (zh) * | 2022-12-29 | 2024-07-02 | 中国科学院深圳先进技术研究院 | 一种糖环修饰的核苷亚磷酰胺单体及其制备方法和应用 |
| US20240309383A1 (en) | 2023-02-24 | 2024-09-19 | Suzhou Sanegene Bio Inc. | Small interfering rna targeting hbv and uses thereof |
| WO2024186673A2 (en) | 2023-03-03 | 2024-09-12 | Sanegene Bio Usa Inc. | Small interfering rna targeting apoc3 and uses thereof |
| WO2024208249A1 (zh) * | 2023-04-06 | 2024-10-10 | 上海舶望制药有限公司 | 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸 |
| WO2024227059A2 (en) | 2023-04-27 | 2024-10-31 | Aligos Therapeutics, Inc. | Short interfering nucleic acid (sina) molecules targeting angptl 3 and angptl 8 and methods of using the same |
| EP4709735A1 (en) | 2023-05-08 | 2026-03-18 | Eli Lilly and Company | Oligonucleotide synthesis using cyclic-phosphorous nucleosides |
| WO2024233864A2 (en) | 2023-05-10 | 2024-11-14 | Dicerna Pharmaceuticals, Inc. | Galnac-conjugated rnai oligonucleotides |
| KR20260018067A (ko) | 2023-05-26 | 2026-02-06 | 일라이 릴리 앤드 캄파니 | 신규 SCN10A RNAi 작용제 및 그의 용도 |
| AU2024280186A1 (en) | 2023-05-31 | 2025-12-04 | Tuojie Biotech (Shanghai) Co., Ltd. | Dsrna targeting lpa and use thereof |
| WO2024259190A2 (en) * | 2023-06-15 | 2024-12-19 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
| EP4731764A2 (en) | 2023-06-21 | 2026-04-29 | Sanegene Bio USA Inc. | Double stranded rna targeting proprotein convertase subtilisin kexin 9 (pcsk9) and methods of use thereof |
| US20250064939A1 (en) | 2023-07-24 | 2025-02-27 | Sanegene Bio Usa Inc. | Lipid-based enhancement agent for rna delivery and therapy |
| AR133386A1 (es) | 2023-07-28 | 2025-09-24 | Dicerna Pharmaceuticals Inc | Composiciones y métodos para la expresión del receptor del ligando de muerte programada (pd-l1) |
| IL326586A (en) * | 2023-08-17 | 2026-04-01 | Adarx Pharmaceuticals Inc | Oligonucleotides containing a ligand at a nitrogenous base, at the '2' position, or at the '3' position |
| WO2025054459A1 (en) | 2023-09-08 | 2025-03-13 | Dicerna Pharmaceuticals, Inc. | Rnai oligonucleotide conjugates |
| WO2025228441A2 (en) | 2024-04-30 | 2025-11-06 | Sanegene Bio Usa Inc. | Small interfering rna targeting inhbe and uses thereof |
| WO2025250605A1 (en) | 2024-05-31 | 2025-12-04 | Eli Lilly And Company | Acvr2a and acvr2b rna interference agents |
| TW202606725A (zh) * | 2024-06-14 | 2026-02-16 | 美商艾拉倫製藥公司 | ５＇－經修飾之單體、寡核苷酸及雙股ｒｎａ |
| WO2025259992A1 (en) * | 2024-06-14 | 2025-12-18 | Alnylam Pharmaceuticals, Inc. | 5'-modified monomers, oligonucleotides and double-stranded rnas |
| WO2025264952A2 (en) | 2024-06-21 | 2025-12-26 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| WO2025264948A2 (en) | 2024-06-21 | 2025-12-26 | Eli Lilly And Company | Inhbe rna interference agents |
| WO2026006109A2 (en) | 2024-06-24 | 2026-01-02 | Eli Lilly And Company | Novel rna therapeutics and uses thereof |
| WO2026017140A2 (en) | 2024-07-18 | 2026-01-22 | Sanegene Bio Usa Inc. | Small interfering rna targeting fxi and uses thereof |
| WO2026030418A2 (en) | 2024-07-31 | 2026-02-05 | Eli Lilly And Company | Oligonucleotide synthesis using cyclic-phosphorous nucleosides |
| WO2026041067A2 (en) | 2024-08-20 | 2026-02-26 | Sanegene Bio Usa Inc. | Small interfering rna targeting myostatin (mstn) and uses thereof |
| WO2026041910A2 (en) | 2024-08-21 | 2026-02-26 | Novo Nordisk A/S | Compositions and methods for inhibiting xdh expression |
| WO2026046411A1 (en) | 2024-09-02 | 2026-03-05 | Sanegene Bio Usa Inc. | Small interfering rna targeting plasminogen (plg) and uses thereof |
| WO2026092658A2 (en) | 2024-10-31 | 2026-05-07 | Sanegene Bio Usa Inc. | Small interfering rna targeting amyloid beta precursor protein (app) and uses thereof |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
| US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
| US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
| WO1989009221A1 (en) | 1988-03-25 | 1989-10-05 | University Of Virginia Alumni Patents Foundation | Oligonucleotide n-alkylphosphoramidates |
| US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
| US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
| US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
| CA2479846C (en) * | 1989-05-15 | 2007-07-24 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic | Phosphonomethoxymethylpurine/pyrimidine derivatives |
| US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
| US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US6001840A (en) | 1990-03-06 | 1999-12-14 | Southern Research Institute | Methods of treatment of viral infections using carbocyclic deoxyguanosine analogs |
| US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
| US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
| US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
| US5998603A (en) | 1994-09-29 | 1999-12-07 | Isis Pharmaceuticals, Inc. | 4'-desmethyl nucleoside analogs, and oligomers thereof |
| US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
| US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
| US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
| US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
| US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
| JPH06502300A (ja) | 1990-08-03 | 1994-03-17 | サノフィ | 遺伝子発現の抑制のための化合物及び方法 |
| US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
| US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
| US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
| EP0549686A4 (en) | 1990-09-20 | 1995-01-18 | Gilead Sciences Inc | Modified internucleoside linkages |
| US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
| US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
| CA2159629A1 (en) | 1993-03-31 | 1994-10-13 | Sanofi | Oligonucleotides with amide linkages replacing phosphodiester linkages |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
| US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
| US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| WO1998051278A2 (en) | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| CA2303299C (en) * | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
| EP2138191A1 (en) | 1998-01-05 | 2009-12-30 | University Of Washington | Enhanced transport using membrane disruptive agents |
| WO2001051092A2 (en) | 2000-01-07 | 2001-07-19 | University Of Washington | Enhanced transport of agents using membrane disruptive agents |
| DE60115044T2 (de) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Liposomale antineoplastische arzneimittel und deren verwendungen |
| KR100872437B1 (ko) | 2000-12-01 | 2008-12-05 | 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. | Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자 |
| WO2003040395A2 (en) | 2001-11-07 | 2003-05-15 | Applera Corporation | Universal nucleotides for nucleic acid analysis |
| US20030190626A1 (en) * | 2002-04-09 | 2003-10-09 | Vasulinga Ravikumar | Phosphorothioate monoester modified oligomers |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| PL1628685T3 (pl) | 2003-04-25 | 2011-05-31 | Gilead Sciences Inc | Przeciwwirusowe analogi fosfonianowe |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| US20070265220A1 (en) | 2004-03-15 | 2007-11-15 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded RNA |
| ATE450251T1 (de) | 2004-05-17 | 2009-12-15 | Tekmira Pharmaceuticals Corp | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
| WO2007109584A1 (en) | 2006-03-16 | 2007-09-27 | University Of Washington | Temperature-and ph-responsive polymer compositions |
| BRPI0715375A2 (pt) | 2006-08-18 | 2013-06-18 | Hoffmann La Roche | policonjugados para distribuiÇço in vivo de polinucleotÍdeos |
| WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
| US20110250138A1 (en) | 2007-08-01 | 2011-10-13 | Alnylam Pharmaceuticals, Inc. | Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand |
| CN102065902A (zh) | 2008-05-13 | 2011-05-18 | 华盛顿大学 | 聚合物载体 |
| WO2009140423A2 (en) | 2008-05-13 | 2009-11-19 | University Of Washington | Targeted polymer bioconjugates |
| ES2404136T3 (es) | 2008-05-13 | 2013-05-24 | University Of Washington | Ensamblajes micelares |
| ES2404131T3 (es) | 2008-05-13 | 2013-05-24 | University Of Washington | Copolímeros de dibloques y sus complejos con polinucleótidos para el suministro en células |
| CA2724472A1 (en) | 2008-05-13 | 2009-11-19 | University Of Washington | Micelles for intracellular delivery of therapeutic agents |
| JP2012500793A (ja) | 2008-08-22 | 2012-01-12 | ユニヴァーシティ オブ ワシントン | 細胞内デリバリーのための異種性ポリマーミセル |
| JP2012504389A (ja) | 2008-09-22 | 2012-02-23 | ダイセルナ ファーマシューティカルズ， インコーポレイテッド | 修飾を有するｄｓＲＮＡによる遺伝子発現の特異的な阻害のための組成物および方法 |
| WO2010048585A2 (en) | 2008-10-24 | 2010-04-29 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
| US20110281934A1 (en) | 2008-11-06 | 2011-11-17 | Phaserx, Inc. | Micelles of hydrophilically shielded membrane-destabilizing copolymers |
| CA2742880A1 (en) | 2008-11-06 | 2010-05-14 | University Of Washington | Multiblock copolymers |
| EP2379083B1 (en) | 2008-12-18 | 2017-08-16 | Dicerna Pharmaceuticals, Inc. | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2010093788A2 (en) | 2009-02-11 | 2010-08-19 | Dicerna Pharmaceuticals, Inc. | Multiplex dicer substrate rna interference molecules having joining sequences |
| TR201811076T4 (tr) | 2009-06-10 | 2018-08-27 | Arbutus Biopharma Corp | Geliştirilmiş lipit formulasyonu. |
| WO2011005860A2 (en) * | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
| JP2013504585A (ja) * | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| EP2601204B1 (en) * | 2010-04-28 | 2016-09-07 | Ionis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
| ES2605990T3 (es) | 2010-12-29 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos |
| KR20150055037A (ko) | 2012-09-14 | 2015-05-20 | 다이서나 파마수이티컬, 인크. | 이중쇄 rna에 의한 myc의 특이적 저해를 위한 방법 및 조성물 |
| JP2016507484A (ja) * | 2012-12-06 | 2016-03-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ジスルフィドマスキングプロドラッグ組成物および方法 |
| EP2968149B1 (en) | 2013-03-14 | 2024-05-08 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
| US10119136B2 (en) | 2014-01-09 | 2018-11-06 | Alnylam Pharmaceuticals, Inc. | RNAi agents modified at the 4′-C position |
| ES2747842T3 (es) | 2014-12-15 | 2020-03-11 | Dicerna Pharmaceuticals Inc | Acidos nucleicos de doble hebra modificados por ligando |
| AU2015363042B2 (en) | 2014-12-15 | 2021-02-25 | Emory University | Phosphoramidates for the treatment of Hepatitis B virus |
| IL296496B2 (en) | 2014-12-26 | 2024-10-01 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| EP3067369A1 (en) | 2015-03-11 | 2016-09-14 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Methods and compositions for the treatment of anti-angiogenic resistant cancer |
| WO2016174081A1 (en) | 2015-04-28 | 2016-11-03 | Ku Leuven Research & Development | Novel antiviral compounds, a process for their preparation, and their use for treating viral infections |
| CN114891053A (zh) | 2016-08-23 | 2022-08-12 | 迪克纳制药公司 | 包含可逆修饰的寡核苷酸的组合物及其用途 |
-
2017
- 2017-09-01 WO PCT/US2017/049909 patent/WO2018045317A1/en not_active Ceased
- 2017-09-01 CN CN201780068124.5A patent/CN110072530B/zh active Active
- 2017-09-01 PT PT178476388T patent/PT3506909T/pt unknown
- 2017-09-01 MX MX2019002339A patent/MX2019002339A/es unknown
- 2017-09-01 HU HUE17847638A patent/HUE059718T2/hu unknown
- 2017-09-01 ES ES17847638T patent/ES2924806T3/es active Active
- 2017-09-01 CA CA3033756A patent/CA3033756A1/en active Pending
- 2017-09-01 US US16/328,546 patent/US11414659B2/en active Active
- 2017-09-01 PL PL17847638.8T patent/PL3506909T3/pl unknown
- 2017-09-01 EP EP17847638.8A patent/EP3506909B1/en active Active
- 2017-09-01 JP JP2019511707A patent/JP6978099B2/ja active Active
- 2017-09-01 DK DK17847638.8T patent/DK3506909T3/da active
- 2017-09-01 KR KR1020197008956A patent/KR102350647B1/ko active Active
- 2017-09-01 KR KR1020227000736A patent/KR102493872B1/ko active Active
- 2017-09-01 AU AU2017321892A patent/AU2017321892A1/en not_active Abandoned
- 2017-09-01 EP EP22175611.7A patent/EP4101859A1/en active Pending
-
2019
- 2019-02-18 IL IL264887A patent/IL264887B/en unknown
-
2021
- 2021-11-04 JP JP2021180199A patent/JP2022017481A/ja not_active Withdrawn
- 2021-11-25 IL IL288418A patent/IL288418A/en unknown
-
2022
- 2022-07-07 US US17/859,781 patent/US12037586B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022106928A (ja) | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 | |
| ES2924806T3 (es) | Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo | |
| US20170362270A1 (en) | Modified oligonucleotides and methods for their synthesis | |
| JP2019526555A5 (enExample) | ||
| JP6542662B2 (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| CN103052711A (zh) | 具有含氮脂环式骨架的单链核酸分子 | |
| JP2022513111A5 (enExample) | ||
| EP3366774A1 (en) | Nucleic acid complex having at least one bulge structure | |
| JP6634095B2 (ja) | プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途 | |
| WO2026073042A1 (en) | Oligonucleotide compositions and methods thereof | |
| WO2026073043A2 (en) | Oligonucleotide compositions and methods thereof | |
| CN118475355A (zh) | 肾毒性减轻剂 | |
| WO2025072879A1 (en) | Oligonucleotide compositions and methods thereof | |
| WO2023282344A1 (ja) | 腎毒性軽減剤 | |
| US10337009B2 (en) | Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression | |
| HK40084990A (en) | 4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same | |
| NZ750307B2 (en) | Compositions comprising reversibly modified oligonucleotides and uses thereof | |
| HK40005478A (en) | Compositions comprising reversibly modified oligonucleotides and uses thereof |